NOV 04, 2021 5:00 PM PDT

The first FDA approved eye drops to treat presbyopia and correct poor near-vision.

WRITTEN BY: J. Bryce Ortiz

Your Grandma’s favorite eyeglasses may soon find their way to the trashcan. Last Friday, October 29th, the United States Food and Drug Administration (FDA) approved for use the first-of-its-kind daily eyedrops to treat presbyopia, an eye condition that makes seeing close objects difficult. 

Presbyopia, from the Greek for “old eye,” is a common age-related loss of the eyes’ ability to focus on close objects and is caused when the lens of the eye becomes less flexible. In normal eyesight, the lens can change shape to help focus light onto the retina and this enables us to see things both up close and far away. But because the lens is more rigid in Presbyopia, the lens is unable to efficiently focus light on the retina leading to poor visual acuity with close objects. As such, as we age, many individuals rely on “reading” glasses to see nearby objects such as words in a book. Presbyopia affects close to 128 million Americans and begins to progress starting at the age of 40. The recent FDA approval of Vuity (pilocarpine HCl ophthalmic solution) is an exciting announcement for individuals who suffer from presbyopia. 

Vuity is the first and only FDA-approved eye drop to treat presbyopia and requires a once-daily eye drop to help with visual acuity. Vuity works by constricting the pupil of the eyes to enhance the depth of focus, while still maintaining pupillary response to various lighting conditions. Importantly, the drops work quickly (within 15 minutes) and last throughout the day. Dr. George Waring, Director of the Waring Vision Institute in South Carolina, stated that, “I am particularly encouraged by the rapid onset of action and duration of efficacy for Vuity to improve near and intermediate vision without impacting distance vision with one drop daily, particularly for those with mild to moderate presbyopia.”

The approval of Vuity by the FDA is based on recent clinical studies that evaluated the safety and efficacy of the eyedrops in patients with presbyopia. In the clinical trials, individuals with presbyopia were treated with Vuity once daily for 30 days and then given a visual assessment. When the patients treated with Vuity were compared to individuals who received placebo eyedrops, the data showed that Vuity led to statistically significant improvements in near-vision reading with very few adverse side effects. AbbVie, the pharmaceutical company that designed and manufacturers Vuity, is hoping to improve the lives of millions of individuals with this new eye drop. Michael Servino, vice chairman and president of AbbVie, said, “We are proud to offer Vuity as a first-of-its-kind once-daily eye drop that we believe will change the way people and their eye doctors approach presbyopia.”

 

Sources: PrNewswireWebMDAmerican Academy of OphthalmologyInvestigative Ophthalmology and Visual Science

About the Author
  • Science and medical writer | Researcher | Interested in the intersection between translational science, drug development, and policy
You May Also Like
NOV 30, 2021
Immunology
Sweet Escape: A Sugar Molecule Helps HIV Remain Incognito
NOV 30, 2021
Sweet Escape: A Sugar Molecule Helps HIV Remain Incognito
HIV is a master of disguise. Once the virus enters the body, it has a number of sophisticated mechanisms through which i ...
DEC 02, 2021
Immunology
New mRNA Vaccine Stops Ticks, Prevents Lyme Disease
DEC 02, 2021
New mRNA Vaccine Stops Ticks, Prevents Lyme Disease
Yale University researchers have developed an mRNA vaccine against ticks that could help prevent Lyme disease. This is a ...
NOV 30, 2021
Cannabis Sciences
To Trust or Not to Trust the Process: Bioreactive Chemical Variation in Cannabis Extracts Based on Extraction Method
NOV 30, 2021
To Trust or Not to Trust the Process: Bioreactive Chemical Variation in Cannabis Extracts Based on Extraction Method
With cannabis legislation becoming increasingly less restrictive over the past 20 years, consumers have found themselves ...
DEC 07, 2021
Microbiology
Gut Microbes Could Help Protect Us From Viral Infection, Including COVID-19
DEC 07, 2021
Gut Microbes Could Help Protect Us From Viral Infection, Including COVID-19
The human microbiome is closely connected to our immune system. Our bodies have to be able to keep the bacterial populat ...
JAN 04, 2022
Drug Discovery & Development
Micro-robots that can deliver drugs to treat brain cancer
JAN 04, 2022
Micro-robots that can deliver drugs to treat brain cancer
Scientists have developed tiny, microscopic robots with the capability to swim through the bloodstream, enter the brain, ...
JAN 20, 2022
Drug Discovery & Development
Review Finds Improved Transparency Among Antidepressant Drug Trials
JAN 20, 2022
Review Finds Improved Transparency Among Antidepressant Drug Trials
Trials relating to newly developed antidepressant drugs are becoming more transparent. The corresponding study was publi ...
Loading Comments...